About the Event
Each year as many as 15,000 babies in the U.S. develop Bronchopulmonary Dysplasia (BPD), a condition that is the leading cause of death in premature infants.
AyuVis is a biopharmaceutical company dedicated to helping pre-term babies grow into normal, healthy adults. They have developed a first-in-class, small molecule, preventative therapeutic for BPD that has shown great promise in pre-clinical testing thanks to its dual anti-inflammatory and anti-microbial activities.Because of the severity of the disease and urgency of the need, the program has been granted Orphan Drug and Rare Pediatric Drug Designations by the U.S. FDA. The company has completed the Pre-IND meeting and is in the process of its Phase 1 filing.
Please join our webinar to hear from AyuVis founder and CEO, Dr. Suchi Acharya, who will talk about the dire need for this therapy and the rapid progress that’s being made in saving the lives of these most vulnerable babies.
Watch On-Demand Webinar